The Effect of Combined General-epidural vs General Anaesthesia on Postoperative Gastrointestinal Surgery

NCT ID: NCT03056261

Last Updated: 2017-02-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-30

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sixty neonates and infants will be enrolled and randomised into two groups of n=30 each . For their surgical procedures, one group general (GA) anaesthesia the second group will receive a combined general and epidural anaesthesia (CGEA).

Anaesthetic technique:

Patients in the GA group will be induced with intravenous propofol (2-4 mg.kg-1) and fentanyl (2-4 µg.kg-1) and will receive rocuronium bromide (0.5 mg.kg-1) to facilitate endotracheal intubation. Anaesthesia will be maintained with sevoflurane (2-3%) in an air/oxygen mixture as well as intravenous fentanyl as required.

In the (CGEA) 0.5 ml.kg-1 of 0.25% bupivacaine will be injected into the epidural catheter, followed by a continuous infusion of 0.1% bupivacaine at a rate of 0.2 mg.kg-1.hr-1 for up to 48 hours postoperatively. Assessment of anaesthetic efficacy will be measured Intraoperative care vital signs. And will continuously be monitored with a Datex AS/3 (Engestrom®, Helsinki, Finland) monitor.

The use of antibiotic prophylaxis will be determined by the degree of bowel contamination during surgery, with the commonest regimen consisting of penicillin, gentamicin and metronidazole will be administered. Antibiotics will be continued for 36-48 hours postoperatively to prevent infection arising from the disturbed bowel flora.

Postoperative care, following surgery, will be conducted. The feeding volume will be increased in steps as long as the volume of regurgitated fluid will be less than 20% of the administered breast milk or formula volume. Full feeding will define as oral tolerance of at least 80% of daily maintenance volume. In cases of abdominal distension or vomiting, feeding will withheld until symptom resolution. The nasogastric tube will be removed on bowel function restoration The CRIES score will be use to assess the severity and duration of postoperative pain during the patients' NICU stay. If the CRIES score is ≥4, fentanyl will be continuously intravenously infused in both study group. Fentanyl will be also administered to CGEA patients who experienced pain despite a continuous epidural infusion at 1-5 µg.kg-1.h-1. The amount of fentanyl required for adequate postoperative pain relief will be recorded in both groups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After approval off the local Ethical Committee of Bnai Zion Hospital, Haifa, Israel and informed parental consent obtained for each participant. Sixty small infants who undergoing GI surgery will be enrolled in this study.

The inclusion criteria are neonates or infants requiring the following major intestinal procedures: duodenoduodenostomy or duodenojejunostomy for duodenal atresia, ileocaecal resection for intestinal volvulus, ileostomy or colostomy closure for congenital anorectal malformations, and corrective surgery for Hirschsprung's disease. The exclusion criteria are concurrent coagulopathies, sepsis, vertebral column malformations, neurological disease, immunocompromise with or without leukopenia, and intestinal necrotising enterocolitis. Patients will be also excluded if they will require exploratory laparotomy or emergent intestinal surgery.

Sixty premature, ex-premature, and full-term neonates and infants meeting the above criteria will enrolled in the study, patients will randomised into two groups of n=30 each ( according to a computer program ) . For their surgical procedures, the first group will receive general anesthesia (GA group), whereas the second group receive combined general and epidural anesthesia (CGEA group).

Anesthetic technique Patients in the GA group will be induced with intravenous propofol (2-4 mg.kg-1) and fentanyl (2-4 µg.kg-1) and receive rocuronium bromide (0.5 mg.kg-1) to facilitate endotracheal intubation. Anaesthesia will be maintained with sevoflurane (2-3%) in an air/oxygen mixture as well as intravenous fentanyl as required.

Patients in the CGEA group will be induce as above in addition to receiving epidural anaesthesia as follows: A 20G epidural catheter (B. Braun Medical Ltd., Melsungen, Germany) through a 19G Crawford epidural needle, so that its tip lays between the desired T5 and T10 spinal segments. Correct catheter placement will be confirmed by portable epidurography after filling the catheter with 0.5 ml iohexol (Omnipaque® 300, Nycomed, Oslo, Norway). A test dose of 0.1 ml.kg-1 of 1% lidocaine with 1:200 000 adrenaline will be administered, and the result and effects on heart rate (HR) and the ST segment will be noted. If the HR increases by at least 20% above baseline and/or ST segment changes will be observed, the catheter will be withdrawl and re positioned. 0.5 ml.kg-1 of 0.25% bupivacaine will be injected into the epidural catheter, followed by a continuous infusion of 0.1% bupivacaine at a rate of 0.2 mg.kg-1.hr-1 for up to 48 hours postoperatively.

Assessment of anesthetic efficacy in both groups will be confirmed by the absence of surges in blood pressure (BP) and HR beyond 20% above baseline. Success of epidural anesthesia will be defined by the correct placement of the epidural catheter between the T5 and T10 spinal segments within two attempts, as well as the obviation for additional systemic analgesia. In cases of epidural technique failure, anesthesia will be maintained by GA and the patient will be removed from the study.

Intraoperative care Intraoperative systolic, diastolic and mean arterial pressures (SBP, DBP, and MAP), HR, arterial oxygen saturation(SaO2), and temperature will be continuously monitored with a Datex AS/3 (Engestrom®, Helsinki, Finland) monitor. All patients in the GA group will mechanically be ventilated, with maintenance of peak inspiratory pressure between 18 and 30 cmH20, and end-tidal CO2 (ETCO2) between 30 and 50 mmHg. Additionally, urine output will be measured at 30-minute intervals.

Two peripheral intravenous cannulae will be inserted preoperatively for each patient, and fluid will be maintained with Ringer's lactate and 5% glucose solutions at 4 ml.kg-1.h-1. Additional Ringer's lactate will be infused for fluid replacement of third-space and/or blood losses. Packed red blood cells will be transfused in cases of blood loss ≥10% of blood volume.

The use of antibiotic prophylaxis will be determined by the degree of bowel contamination during surgery, with the commonest regimen consisting of penicillin, gentamicin and metronidazole will be administered. Antibiotics will continue for 36-48 hours postoperatively to prevent infection arising from the disturbed bowel flora.

Postoperative care following surgery, all patients will be transferred to the neonatal intensive care unit (NICU) where physiological monitoring and mechanical ventilation will continue as appropriate. Blood samples will be collected postoperatively for full blood count, glucose, electrolyte, and blood gas measurement.

The feeding volume will be increased in 5 ml steps as long as the volume of regurgitated fluid is less than 20% of the administered breast milk or formula volume. Full feeding will be defined as oral tolerance of at least 80% of daily maintenance volume. In cases of abdominal distension or vomiting, feeding will withheld until symptom resolution. The nasogastric tube will be removed on bowel function restoration (i.e. defaecation).

The CRIES neonatal postoperative pain score (C=Crying; R=Requires oxygen; I=Increased vital signs; E=Expression; S=Sleepless) \[18\] will be used to assess the severity and duration of postoperative pain during the patients' NICU stay. Scoring will carried out by the attending nurses every two hours. If the CRIES score is ≥4, fentanyl will be continuously intravenously infused in both study group. Fentanyl will be also administered to CGEA patients who experienced pain despite a continuous epidural infusion at 1-5 µg.kg-1.h-1. The amount of fentanyl required for adequate postoperative pain relief will recorded in both groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epidural Anesthesia Infection Infant, Newborn, Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

comaring combined general anesthesia and epidural technique to general anaesthsia alone or gastrointestinal recovery and pain managment
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combined general and epidural

Combined general and epidural anesthesia in infants UNDERGOING INTESTINAL SURGERY

Group Type EXPERIMENTAL

Combined general and epidural

Intervention Type PROCEDURE

Combined general and epidural anaesthesia

General anaesthesia

General anesthesia in infants UNDERGOING INTESTINAL SURGERY

Group Type PLACEBO_COMPARATOR

General anaesthesia

Intervention Type PROCEDURE

General anaesthesia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combined general and epidural

Combined general and epidural anaesthesia

Intervention Type PROCEDURE

General anaesthesia

General anaesthesia

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Neonates or infants requiring the following major intestinal procedures: duodenoduodenostomy or duodenojejunostomy for duodenal atresia,
* ileocaecal resection for intestinal volvulus,
* ileostomy or colostomy closure for congenital anorectal malformations,
* corrective surgery for Hirschsprung's disease. emergent intestinal surgery.

Exclusion Criteria

* sepsis,
* vertebral column malformations,
* neurological disease,
* immunocompromise with or without leukopenia,
* intestinal necrotising enterocolitis.
* Patients will be also excluded if they required exploratory laparotomy or or emergent intestinal surgery
Minimum Eligible Age

1 Month

Maximum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bnai Zion Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

MOSTAFA.SOMRI

Prof Mostafa Somri

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mostafa Somri, M.D.

Role: PRINCIPAL_INVESTIGATOR

Bnai Zion Medical Center

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mostafa Somri, MD

Role: CONTACT

#972-4-8359346

References

Explore related publications, articles, or registry entries linked to this study.

Gannam-Somri L, Matter I, Hadjittofi C, Vaida S, Khalaily H, Hossein J, Somri M. Combined epidural-general anaesthesia vs general anaesthesia in neonatal gastrointestinal surgery: A randomized controlled trial. Acta Anaesthesiol Scand. 2020 Jan;64(1):34-40. doi: 10.1111/aas.13469. Epub 2019 Oct 7.

Reference Type DERIVED
PMID: 31506919 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BnaiZionMC-16-MS-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.